Publications by authors named "Jennifer Diamond"

Claim this Profile
C
Cardiorespiratory Fitness, Physical Activity, Sedentary Behavior, and Diabetes Risk Among Breast Cancer Survivors Treated with Endocrine Therapies.
Heather J Leach, Matthew Bolt, Ethan W Clark, Sara E Hull, Jennifer R Diamond

Med Sci Sports Exerc· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer.
Elena Shagisultanova, Hannah Parris, Long Liu, Stephanie Giangiuli, Dexiang Gao, Jennifer R Diamond

Clin Breast Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifetime fitness benefits of short-distance dispersal and low costs of inbreeding drive inbreeding tolerance in an avian cooperative breeder.
Shailee S Shah, Jennifer Diamond, Sahas Barve, Elissa J Cosgrove, Reed Bowman

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
Tyler P Robin, Junxiao Hu, Bernard L Jones, Taylor Patton, Jennifer R Diamond

Gynecol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center.
Ahmed Alsafar, Sama L Kareem, Bradley R Corr, Christopher H Lieu, Breelyn Wilky, Jennifer R Diamond

Front Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer.
Anna R Schreiber, Stephen G Smoots, Marilyn M Jackson, Stacey M Bagby, Evan D Dus, Jennifer R Diamond

Front Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast.
Joseph L Sottnik, Madeleine T Shackleford, Camryn S Nesiba, Amanda L Richer, Zoe Fleischmann, Jennifer R Diamond

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.
Anthony D Elias, Alyse W Staley, Monica Fornier, Gregory A Vidal, Vida Alami, Jennifer R Diamond

NPJ Breast Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.
S Lindsey Davis, Wells A Messersmith, W Thomas Purcell, Elaine T Lam, Bradley R Corr, Jennifer R Diamond

Cancers (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Stephen G Smoots, Anna R Schreiber, Marilyn M Jackson, Stacey M Bagby, Adrian T A Dominguez, Jennifer R Diamond

Breast Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Jennifer R Diamond

J Immunother Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Savannah Roy, Stephanie Lakritz, Anna R Schreiber, Elizabeth Molina Kuna, Cathy J Bradley, Jennifer R Diamond

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.
Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew J Brenner, Jennifer R Diamond

Clin Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.
Anna R Schreiber, Jodi A Kagihara, Bradley R Corr, S Lindsey Davis, Christopher Lieu, Jennifer R Diamond

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Anna R Schreiber, Cindy L O'Bryant, Peter Kabos, Jennifer R Diamond

Expert Rev Anticancer Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Nisha Holay, Alexander Somma, Mark Duchow, Milad Soleimani, Anna Capasso, Jennifer Diamond

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in NUT Carcinoma Harboring a Splice Site Mutation.
Michael L Cheng, Yeying Huang, Nhi Luong, Jaclyn LoPiccolo, Mizuki Nishino, Jennifer R Diamond

JCO Precis Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
Savannah Roy, Stephanie Lakritz, Anna R Schreiber, Elizabeth Molina, Peter Kabos, Jennifer R Diamond

Eur J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
Anthony D Elias, Nicole S Spoelstra, Alyse W Staley, Sharon Sams, Lyndsey S Crump, Jennifer R Diamond

NPJ Breast Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
S Lindsey Davis, Sarah J Hartman, Stacey M Bagby, Marina Schlaepfer, Betelehem W Yacob, Jennifer R Diamond

BMC Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies.
Patrick M Boland, Christos Fountzilas, Marwan Fakih, Mateusz Opyrchal, Jennifer R Diamond

Cancer Chemother Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.
John Hilton, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik, Jennifer R Diamond

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
Wen Wee Ma, Jenny J Li, Nilofer S Azad, Elaine T Lam, Jennifer R Diamond

Cancer Chemother Pharmacol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R Diamond, Sant P Chawla

Clin Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
Lisa A Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Jennifer R Diamond

NPJ Breast Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis